SES AUA 2025 Bladder Cancer

Viewing 1-13 of 13 articles

SES AUA 2025: Evaluation of Systemic Therapy and Surgical Consolidation in Patients with Node Positive UTUC

SES AUA 2025: Association of Somatic Gene Mutations in Urothelial Cancer Based on Location in the Bladder

SES AUA 2025: Development and Initial Experience of a Dedicated Female Bladder Cancer Clinical Care Coordinator Role

SES AUA 2025: Multicenter Experience with First-Line Intravesical Gemcitabine + Docetaxel versus BCG for high risk NMIBC

SES AUA 2025: ENVISION: Primary Chemoablation of Recurrent Low-Grade Intermediate Risk NMIBC with UGN-102: A Single-Arm, Open-Label, Phase 3 Trial

SES AUA 2025: LEGEND: Phase 1/2 Study of Detalimogene Voraplasmid, a Novel, Investigational, Non-Viral Intravesical Gene Therapy for BCG-Unresponsive NMIBC with CIS

SES AUA 2025: Oncologic Efficacy of Reduced versus Standard-Dose BCG for NMIBC

SES AUA 2025: First-in-Human Study of TAR-210 Erdafitinib Intravesical System in Patients with NMIBC with Select FGFR Alterations

SES AUA 2025: Long-Term Outcomes of Primary Chemoablation of Low-Grade UTUC with UGN-101, a Mitomycin Reversal Thermal Gel

SES AUA 2025: TAR-200 in Patients with BCG-Unresponsive High-Risk NMIBC: Results from the SunRISe-1 Study

SES AUA 2025: Encore Results: BOND-003 Cohort C – A Phase 3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for BCG-Unresponsive High-Risk NMIBC with CIS

SES AUA 2025: Assessing Hematuria Screening Disparities Using the All of Us Database

SES AUA 2025: Targeting Gemcitabine Resistance in Bladder Cancer via a Biomarker-Guided Pathway